Immunohistochemical (IHC) status of estrogen receptor (ER), progesterone receptor (PgR), HER2, and Ki67, has been adapted to construct molecular breast cancer subtype which can be used to make therapeutic choices [7]. This evidence concerns the gene ERBB2 and breast cancer.